
Samsung Biologics Expands Strategic Manufacturing Agreement with Bristol Myers Squibb
Samsung Biologics and Bristol Myers Squibb have further expanded their strategic manufacturing agreement to include the large-scale manufacture of an antibody cancer drug substance.
Korean contract development and manufacturing organization (CDMO), Samsung Biologics, has announced, in a Sep. 18, 2023 press release, a new agreement for the large-scale manufacturing of an antibody cancer drug substance with global biopharma company Bristol Myers Squibb.
This new agreement between the two companies adds to their long-standing strategic relationship, originally formed in
“Our relationship with Bristol Myers Squibb spans over a decade, and we are proud and excited to help bring important medicines to patients around the world,” said John Rim, president and CEO of Samsung Biologics, in the press release. “This collaboration with Bristol Myers Squibb underscores our commitment to expediting the delivery and ensuring the continuous supply of client pipelines, enabled by our commitment to manufacturing quality, innovation, and capacity.”
According to a
This expanded agreement with Bristol Myers Squibb is another boost to Samsung Biologics’ relationship with Big Pharma. In
Furthermore, earlier in the year (March 2023), Samsung Biologics revealed that its plans to
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.